Related references
Note: Only part of the references are listed.Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
Dennis M Black et al.
Lancet Diabetes & Endocrinology (2020)
Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men
Mark J. Bolland et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Ian R. Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial
Andrew Grey et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2017)
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)
Benjamin Z. Leder et al.
BONE (2017)
Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women A Randomized Clinical Trial
Susan L. Greenspan et al.
JAMA INTERNAL MEDICINE (2015)
Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial
Andrew Grey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Five years of anti-resorptive activity after a single dose of zoledronate - Results from a randomized double-blind placebo-controlled trial
Andrew Grey et al.
BONE (2012)
Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men
Mark J. Bolland et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States
Sarah J. Glover et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
Michael McClung et al.
OBSTETRICS AND GYNECOLOGY (2009)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
